These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 7318921

  • 1. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
    Meller E, Friedman E.
    Eur J Pharmacol; 1981 Nov 19; 76(1):25-9. PubMed ID: 7318921
    [Abstract] [Full Text] [Related]

  • 2. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y, Komori T, Okuda S, Segawa T.
    Arch Int Pharmacodyn Ther; 1979 Jan 19; 237(1):25-30. PubMed ID: 485682
    [Abstract] [Full Text] [Related]

  • 3. Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment.
    Le Douarin C, Oblin A, Fage D, Scatton B.
    Eur J Pharmacol; 1983 Sep 16; 93(1-2):55-62. PubMed ID: 6628547
    [Abstract] [Full Text] [Related]

  • 4. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
    Staunton DA, Magistretti PJ, Shoemaker WJ, Deyo SN, Bloom FE.
    Brain Res; 1982 Jan 28; 232(2):401-12. PubMed ID: 6322915
    [Abstract] [Full Text] [Related]

  • 5. The effects of chronic lithium on behavioral and biochemical indices of dopamine receptor supersensitivity in the rat.
    Pittman KJ, Jakubovic A, Fibiger HC.
    Psychopharmacology (Berl); 1984 Jan 28; 82(4):371-7. PubMed ID: 6427831
    [Abstract] [Full Text] [Related]

  • 6. Modulating role of lithium on dopamine turnover, prolactin release, and behavioral supersensitivity following haloperidol and reserpine.
    McIntyre IM, Kuhn C, Demitriou S, Fucek FR, Stanley M.
    Psychopharmacology (Berl); 1983 Jan 28; 81(2):150-4. PubMed ID: 6415746
    [Abstract] [Full Text] [Related]

  • 7. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
    Le Douarin C, Fage D, Scatton B.
    Life Sci; 1984 Jan 23; 34(4):393-9. PubMed ID: 6694528
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
    Pert A, Rosenblatt JE, Sivit C, Pert CB, Bunney WE.
    Science; 1978 Jul 14; 201(4351):171-3. PubMed ID: 566468
    [Abstract] [Full Text] [Related]

  • 9. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
    de Graaf CJ, Korf J.
    Psychopharmacology (Berl); 1986 Jul 14; 90(1):54-7. PubMed ID: 3094062
    [Abstract] [Full Text] [Related]

  • 10. Apomorphine- and haloperidol-induced change in 3,4-dihydroxyphenylacetic acid content in the mesolimbic-striatum of the developing rat.
    Nomura Y, Oki K, Segawa T.
    J Pharmacobiodyn; 1980 Feb 14; 3(2):111-6. PubMed ID: 7205536
    [Abstract] [Full Text] [Related]

  • 11. Effects of apomorphine on morphine analgesia during the state of dopaminergic supersensitivity after chronic treatment with haloperidol.
    Kamata K, Ogawa K, Noma S, Kameyama T.
    J Pharmacobiodyn; 1986 Jan 14; 9(1):88-94. PubMed ID: 3712211
    [Abstract] [Full Text] [Related]

  • 12. The behavioral and biochemical effects of lithium on dopaminergic agonist-induced supersensitivity.
    Rubin EH, Wooten GF.
    Psychopharmacology (Berl); 1984 Jan 14; 84(2):217-20. PubMed ID: 6438680
    [Abstract] [Full Text] [Related]

  • 13. Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.
    Reches A, Jackson-Lewis V, Fahn S.
    Psychopharmacology (Berl); 1984 Jan 14; 82(4):330-4. PubMed ID: 6427824
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of haloperidol-induced increase in rat striatal or mesolimbic 3,4-dihydroxyphenylacetic acid and homovanillic acid by pretreatment with chronic methamphetamine.
    Toru M, Mataga N, Takashima M, Nishikawa T.
    Psychopharmacology (Berl); 1981 Jan 14; 74(4):316-20. PubMed ID: 6794073
    [Abstract] [Full Text] [Related]

  • 15. Regulation of the synthesis and metabolism of striatal dopamine after disruption of nerve conduction in the medial forebrain bundle.
    Commissiong JW, Slimovitch C, Toffano G.
    Br J Pharmacol; 1990 Apr 14; 99(4):741-9. PubMed ID: 2361171
    [Abstract] [Full Text] [Related]

  • 16. Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment.
    Wheeler SC, Roth RH.
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun 14; 312(2):151-9. PubMed ID: 7190650
    [Abstract] [Full Text] [Related]

  • 17. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
    Seeger TF, Thal L, Gardner EL.
    Psychopharmacology (Berl); 1982 Jun 14; 76(2):182-7. PubMed ID: 6805029
    [Abstract] [Full Text] [Related]

  • 18. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
    Meller E.
    Psychopharmacology (Berl); 1982 Jun 14; 76(3):222-7. PubMed ID: 6808540
    [Abstract] [Full Text] [Related]

  • 19. Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol.
    Umeda Y, Sumi T.
    Eur J Pharmacol; 1990 Nov 27; 191(2):149-55. PubMed ID: 2086236
    [Abstract] [Full Text] [Related]

  • 20. Effects of intranigral administration of dopamine agonists and antagonists and baclofen on concentrations of dopac and dopamine in the striatum and substantia nigra of the rat.
    Wuerthele SM, Friedle NM, Moore KE.
    J Neural Transm; 1979 Nov 27; 45(2):117-27. PubMed ID: 469523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.